Becton, Dickinson and Company Overview
Pro stress-test →Becton, Dickinson and Company (NYSE: BDX) is a leading global medical technology company. Following a reorganization effective October 1, 2025, the company operates through five segments: Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences (Biosciences Diagnostic Solutions). BDX recently completed the spin-off of its Life Sciences & Diagnostic Solutions segment, receiving $4B to be split between debt reduction and share repurchases.
Strategic Profile
Pro stress-test →Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 non-GAAP EPS and $5.25B revenue, surpassing expectations. New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where the company has been doubling down on investments. For fiscal 2026, the company continues to expect new Becton, Dickinson and Company to deliver low single-digit revenue growth.
Competitive Landscape
Pro stress-test →Becton Dickinson competes in the global medical technology sector against established diversified healthcare companies. Primary competitors include companies like Medtronic and Abbott Laboratories in various medical device segments, alongside specialized players in diagnostics and drug delivery systems. BD maintains competitive positioning through innovation in pharmacy automation, biologic drug delivery systems, and diagnostic solutions.
Industry Context
Becton, Dickinson and Company operates in Medical Technology & Devices.
Key facts
Founded: 1897 · Headquarters: Franklin Lakes, New Jersey · Employees: ~85,000 · Revenue: $5.25B (Q1 FY2026) · Market cap: ~$88B